Literature DB >> 19254516

Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients.

Armin Szegedi1, Wim T Jansen, Arjen P P van Willigenburg, Egbert van der Meulen, Hans H Stassen, Michael E Thase.   

Abstract

OBJECTIVE: New evidence indicates that treatment response can be predicted with high sensitivity after 2 weeks of treatment. Here, we assess whether early improvement with antidepressant treatment predicts treatment outcome in patients with major depressive disorder (MDD). DATA SOURCES: Forty-one clinical trials comparing mirtazapine with active comparators or placebo in inpatients and outpatients (all-treated population, N = 6907; intent-to-treat population, N = 6562) with MDD (DSM-III-R or DSM-IV Criteria) were examined for early improvement (>or= 20% score reduction from baseline on the 17-item Hamilton Rating Scale for Depression [HAM-D-17] within 2 weeks of treatment) and its relationship to treatment outcome. STUDY SELECTION: Data were obtained from a systematic search of single- or double-blind clinical trials (clinical trials database, Organon, a part of Schering-Plough Corporation, Oss, The Netherlands). All included trials (a total of 41) employed antidepressant treatment for more than 4 weeks and a maximum of 8 weeks. The studies ranged from March 1982 to December 2003. Trials were excluded if there were no HAM-D-17 ratings available, no diagnosis of MDD, or if the study was not blinded. Trials were also excluded if HAM-D-17 assessments were not available at week 2, week 4, and at least once beyond week 4. DATA SYNTHESIS: Early improvement predicted stable response and stable remission with high sensitivity (>or= 81% and >or= 87%, respectively). Studies utilizing rapid titration vs. slow titration of mirtazapine demonstrated improved sensitivity for stable responders (98%, [95% CI = 93% to 100%] vs. 91% [95% CI = 89% to 93%]) and stable remitters (100%, [95% CI = 92% to 100%] vs. 93% [95% CI = 91% to 95%]). Negative predictive values for stable responders and stable remitters were much higher (range = 82%-100%) than positive predictive values (range = 19%-60%).
CONCLUSIONS: These results indicate that early improvement with antidepressant medication can predict subsequent treatment outcome with high sensitivity in patients with major depressive disorder. The high negative predictive values indicate little chance of stable response or stable remission in the absence of improvement within 2 weeks. A lack of improvement during the first 2 weeks of therapy may indicate that changes in depression management should be considered earlier than conventionally thought. ©Copyright 2009 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19254516     DOI: 10.4088/jcp.07m03780

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  83 in total

1.  Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses.

Authors:  Ralitza Gueorguieva; Craig Mallinckrodt; John H Krystal
Journal:  Arch Gen Psychiatry       Date:  2011-12

2.  Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder.

Authors:  Boadie W Dunlop; Thomas Li; Susan G Kornstein; Edward S Friedman; Anthony J Rothschild; Ron Pedersen; Philip Ninan; Martin Keller; Madhukar H Trivedi
Journal:  J Psychiatr Res       Date:  2010-06-02       Impact factor: 4.791

3.  Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI.

Authors:  Stella Bitran; Amy H Farabaugh; Victoria E Ameral; Rachel A LaRocca; Alisabet J Clain; Maurizio Fava; David Mischoulon
Journal:  Int Clin Psychopharmacol       Date:  2011-07       Impact factor: 1.659

4.  Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression.

Authors:  David E Kemp; Stephen J Ganocy; Martin Brecher; Berit X Carlson; Suzanne Edwards; James M Eudicone; Gary Evoniuk; Wim Jansen; Andrew C Leon; Margaret Minkwitz; Andrei Pikalov; Hans H Stassen; Armin Szegedi; Mauricio Tohen; Arjen P P Van Willigenburg; Joseph R Calabrese
Journal:  J Affect Disord       Date:  2010-11-10       Impact factor: 4.839

5.  Respiratory sinus arrhythmia reactivity to a sad film predicts depression symptom improvement and symptomatic trajectory.

Authors:  Vanessa Panaite; Alexandra Cowden Hindash; Lauren M Bylsma; Brent J Small; Kristen Salomon; Jonathan Rottenberg
Journal:  Int J Psychophysiol       Date:  2015-12-08       Impact factor: 2.997

6.  Evaluation of a Clinical Pharmacist-Led Multidisciplinary Antidepressant Telemonitoring Service in the Primary Care Setting.

Authors:  Shubha Bhat; Miranda E Kroehl; Katy E Trinkley; Zeta Chow; Lauren J Heath; Sarah J Billups; Danielle F Loeb
Journal:  Popul Health Manag       Date:  2017-12-06       Impact factor: 2.459

Review 7.  Anxious depression: clinical features and treatment.

Authors:  Sanjai Rao; Sidney Zisook
Journal:  Curr Psychiatry Rep       Date:  2009-12       Impact factor: 5.285

8.  High expectancy and early response produce optimal effects in sertraline treatment for post-traumatic stress disorder.

Authors:  Belinda Graham; Natalia M Garcia; Mark S Burton; Andrew A Cooper; Peter P Roy-Byrne; Matig R Mavissakalian; Norah C Feeny; Lori A Zoellner
Journal:  Br J Psychiatry       Date:  2018-10-25       Impact factor: 9.319

9.  Early improvement with lithium in classic mania and its association with later response.

Authors:  Rodrigo Machado-Vieira; David A Luckenbaugh; Marcio G Soeiro-de-Souza; Getulio Marca; Ioline D Henter; Joao V Busnello; Wagner F Gattaz; Carlos A Zarate
Journal:  J Affect Disord       Date:  2012-08-17       Impact factor: 4.839

Review 10.  An update on antidepressant use in bipolar depression.

Authors:  Michelle M Sidor; Glenda M MacQueen
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.